Soleno Therapeutics (SLNO) Competitors $68.57 -1.23 (-1.76%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$68.60 +0.03 (+0.04%) As of 08/22/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. FEMY, IMVT, SNN, SOLV, PEN, STVN, IRTC, GKOS, BLCO, and TMDXShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), and TransMedics Group (TMDX). These companies are all part of the "medical" sector. Soleno Therapeutics vs. Its Competitors Femasys Immunovant Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation. Do analysts rate SLNO or FEMY? Soleno Therapeutics presently has a consensus price target of $115.09, suggesting a potential upside of 67.84%. Femasys has a consensus price target of $7.33, suggesting a potential upside of 1,184.30%. Given Femasys' higher probable upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SLNO or FEMY? In the previous week, Soleno Therapeutics had 21 more articles in the media than Femasys. MarketBeat recorded 26 mentions for Soleno Therapeutics and 5 mentions for Femasys. Femasys' average media sentiment score of 0.99 beat Soleno Therapeutics' score of 0.78 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 4 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Femasys 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, SLNO or FEMY? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-16.56Femasys$1.63M11.41-$18.82M-$0.86-0.66 Which has more volatility and risk, SLNO or FEMY? Soleno Therapeutics has a beta of -2.56, meaning that its share price is 356% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.58, meaning that its share price is 358% less volatile than the S&P 500. Is SLNO or FEMY more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% Femasys -1,113.72%-713.74%-152.60% Do institutionals and insiders hold more shares of SLNO or FEMY? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 11.5% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummarySoleno Therapeutics beats Femasys on 9 of the 16 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.64B$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-16.5622.9031.3626.05Price / SalesN/A516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book15.175.939.536.60Net Income-$175.85M$31.83M$3.26B$265.65M7 Day Performance-4.27%1.89%2.14%2.00%1 Month Performance-22.11%1.62%3.22%0.46%1 Year Performance51.54%9.25%30.18%18.88% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.5724 of 5 stars$68.57-1.8%$115.09+67.8%+51.5%$3.64BN/A-16.5630News CoverageAnalyst ForecastAnalyst RevisionFEMYFemasys3.2279 of 5 stars$0.78-13.2%$7.33+845.7%-46.6%$29.04M$1.63M0.0030Gap UpIMVTImmunovant3.0333 of 5 stars$14.76-4.5%$35.33+139.4%-53.0%$2.64BN/A0.00120SNNSmith & Nephew SNATS3.1995 of 5 stars$35.96-0.5%$28.00-22.1%+21.5%$15.83B$5.81B0.0017,349News CoveragePositive NewsAnalyst DowngradeSOLVSolventum1.699 of 5 stars$71.89-2.0%$85.75+19.3%+19.6%$12.70B$8.25B13.1322,000News CoveragePositive NewsAnalyst DowngradePENPenumbra4.7753 of 5 stars$239.79-0.3%$300.47+25.3%+26.0%$9.38B$1.19B68.524,500Positive NewsInsider TradeSTVNStevanato Group2.0154 of 5 stars€22.14-6.3%N/A+21.1%€6.70B€1.19B41.005,521Positive NewsIRTCiRhythm Technologies1.309 of 5 stars$160.56+1.3%$157.30-2.0%+141.6%$5.09B$591.84M0.002,000News CoverageAnalyst ForecastInsider TradeGKOSGlaukos4.7351 of 5 stars$86.94+2.7%$127.42+46.6%-29.1%$4.85B$383.48M0.00780News CoverageAnalyst RevisionBLCOBausch + Lomb1.6532 of 5 stars$13.66+0.1%$15.56+13.9%-8.3%$4.83B$4.79B32.4813,500Positive NewsTMDXTransMedics Group2.84 of 5 stars$127.26+11.1%$123.00-3.3%-31.8%$3.90B$441.54M59.33210News CoveragePositive News Related Companies and Tools Related Companies Femasys Alternatives Immunovant Alternatives Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives iRhythm Technologies Alternatives Glaukos Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access